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Abstract
Background: Autism, a heterogeneous disease, is described as a genetic psychiatry disorder.
Recently, abnormalities at the synapse are supposed to be important for the etiology of
autism.SHANK3 (SH3 and multiple ankyrin repeat domains protein) gene encodes a master synaptic
scaffolding protein at postsynaptic density (PSD) of excitatory synapse. Rare mutations and copy
number variation (CNV) evidence suggested SHANK3  as a strong candidate gene for the
pathogenesis of autism.
Methods: We performed an association study between SHANK3 gene polymorphisms and autism
in Chinese Han population. We analyzed the association between five single nucleotide
polymorphisms (SNPs) of the SHANK3 gene and autism in 305 Chinese Han trios, using the family
based association test (FBAT). Linkage disequilibrium (LD) analysis showed the presence of LD
between pairwise markers across the locus. We also performed mutation screening for the rare
de novo mutations reported previously.
Results: No significant evidence between any SNPs of SHANK3 and autism was observed. We did
not detect any mutations described previously in our cohort.
Conclusion: We suggest that SHANK3 might not represent a major susceptibility gene for autism
in Chinese Han population.
Background
Autism is a pervasive developmental disorder mainly
characterized by limited or absent verbal communication,
lacking of reciprocal social interaction or responsiveness
and restricted, stereotypical, and ritualized patterns of
interests and behavior. Autism together with childhood
disintegrative disorder, pervasive not otherwise specified
(PDD-NOS, or atypical autism) and Asperger syndrome
share the similar characteristics and are all included as
autism spectrum disorder (ASD), also known as pervasive
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developmental disorder (PDD). Family and twin studies
have conclusively described autism as a highly heritable
neuropsychiatry disorder with heritability estimates of
over 90% and the environmental factors contributing no
more than 10% [1-3]. Nevertheless, autism is etiologically
heterogeneous.
Shank3 (SH3 and multiple ankyrin repeat domains 3; also
termed ProSAP2, proline-rich synapse-associated protein
2) is a master synaptic scaffolding protein[4,5]. In rats and
human beings, Shank3 is expressed preferentially in cere-
bral cortex and cerebellum[6,7]. With its multiple protein
interaction domains, this molecule directly or indirectly
connects with neurotransmitter receptors and cytoskele-
ton proteins[8,9]. It also participates in the formation,
maturation and enlargement of dendritic spines and is
essential for the formation of functional synapses[10].
Accumulating discoveries indicate that autism's cause may
reside in abnormalities at the synapse[3]. Synapses are the
physical sites through which neurons in the brain connect
with each other into an integrated circuit. In 2003, the
alterations in synaptic function was first proposed to be a
possible cause of autism[11]. Neuroligins are a family of
postsynaptic cell adhesion molecules and may be
involved in the synaptogenesis[12]. Mutations of genes
encoding neuroligins (NLGN3, NLGN4X) were supposed
to be pathogenic for autism and Asperger syndrome[13].
Neuroligin-deficiency mouse models according to these
findings exhibit some deficits that are reminiscent of ASD
in human[14,15]. The "neuroligin autim pathway" was
postulated[3]. Shank3 acts as a binding partner for neuro-
ligins(NLGNs)[16]. It was reported that rare mutations in
SHANK3 may contribute to the pathogenesis of autism.
Durand et al. reported two de novo alterations in
SHANK3 in subjects with ASD but not in control individ-
uals. One is a G insertion, and the other is a deletion of the
terminal 22q13 with the breakpoint in intron8 of
SHANK3[17]. Moessner et al. identified de novo variants
with an A962G exchange in exon8 leading to a hetero-
zygous Q321R substitution[18]. They also reported a het-
erozygous deletion encompassing SHANK3 in a female
proband but in neither parent nor in two unaffected
brothers[18]. Recently Gauthier et al. found a de novo
deletion at an intronic splice site in their autistic patients,
and this deletion will lead to aberrant splicing of the tran-
script[19].  SHANK3  could also belong to the "NLGN
autism pathway"[1].
All these indicate that SHANK3 might be a strong candi-
date gene for autism. Resequencing has been applied to
identify the rare mutations of this gene, but the linkage
and association studies of SHANK3 are still insufficient. In
this study, we attempted to investigate the association
between the SHANK3 gene polymorphisms and autism in
305 Chinese Han trios on a population-based approach
using the family-based association test (FBAT). We also
performed mutation screen of this gene in probands with
autism in order to detect the rare de novo mutations
reported previously.
Methods
Subjects
The sample for this study consisted of 305 Chinese Han
family trios (singleton autistic disorder patients and their
unaffected biological parents). These families were
recruited at the Institute of Mental Health, Peking Univer-
sity, China. Of the 305 autistic child probands, 281 were
male and 24 were female. The mean age of the children at
the time of testing was 11 years (range 3–25 years). Diag-
noses of autism were established by senior psychiatrists.
All patients fulfilled the DSM-IV criteria for autistic disor-
der. The cases were assessed using childhood autism rat-
ing scale (CARS)[20] and autism behavior checklist
(ABC)[21]. Children with fragile × syndrome, tuberous
sclerosis, a previously identified chromosomal abnormal-
ity, dysmorphic features, or any other neurological condi-
tion suspected to be associated with autism were
excluded. All subjects provided written informed consent
for participation in this study. The study was approved by
the Ethics Committee of the Health Science Center,
Peking University.
Genotyping and sequencing
Genomic DNA was extracted from the blood using a Qia-
gen QIAamp DNA Mini Kit. We selected seven single
nucleotide polymorphisms (SNPs) in the SHANK3 gene
according to the dbSNP http://www.ncbi.nlm.nih.gov/
SNP/ and the international HapMap project http://
www.hapmap.org/, including rs9616915(missense poly-
morphism), rs2106112(synonymous polymorphism),
rs6010065, rs13057681(missense polymorphism),
rs2301584(3'UTR), rs41281537 and rs756638. Mutation
screen for the rare de novo mutataion reported previously
was performed by sequencing exon8 (for A962G[18]),
exon21 (for G insertion[17]) and donor splice site G dele-
tion of intron19[19] in all the 305 probands with autism.
The SNPs with frequencies of minor allele frequency
(MAF) in our sample greater than 5% were used as genetic
markers in this study. Three SNPs (rs9616915, rs6010065,
rs13057681) were analyzed by polymerase chain reac-
tion-restriction fragment length polymorphism (PCR-
RFLP) analysis. Direct DNA sequencing was used for ana-
lyzing the other SNPs (rs2106112, rs2301584,
rs41281537, rs756638) and detecting the rare de novo
mutation reported previously. The information of primers
and PCR-RFLP analysis is given in Table 1. The PCR
amplification was performed in a 25 μl volume contain-
ing GC Buffer (TaKaRa), 200 mM of each dNTPs, 0.3 mM
of each primer, 1 U of Taq DNA polymerase, and 40 ng ofBMC Medical Genetics 2009, 10:61 http://www.biomedcentral.com/1471-2350/10/61
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the genomic DNA. The conditions used for PCR amplifi-
cation were an initial denaturation phase at 94°C for 5
min, followed by 36 cycles at 94°C for 30 sec, annealing
at 60–65°C for 30–60 sec, and extension at 72°C for 30
sec, followed by a final extension phase at 72°C for 7 min.
A 15 μL aliquot of the PCR product mixtures was com-
pletely digested with 3 units of restriction enzyme over-
night. Digestion products were visualized through
ethidium bromide staining after electrophoresis in 1%–
3% agarose gels. The DNA sequencing was performed
after cleaning the PCR product using a BigDye Terminator
Cycle Sequencing Ready Reaction Kit with Ampli Taq
DNA polymerase (PE Biosystem). The inner primers were
used for the cycle-sequencing reaction, and the fragments
were separated by electrophoresis on an ABI PRISM 377-
96 DNA Sequencer (Applied Biosystem, Foster city,
U.S.A).
Statistical analyses
Deviation from the Hardy-Weinberg equilibrium (HWE)
for genotype frequency distributions was analyzed using
the Chi-square goodness-of-fit test. To perform single-
and multi-locus tests of association, we used the FBAT
program (v. 1.5.1)[22]. The FBAT program uses a general-
ized score statistic to perform a variety of transmission dis-
equilibrium tests, including haplotype analysis.
Moreover, the FBAT program provides pairwise linkage
disequilibrium (LD) analysis to detect an inter-marker
relationship, using D' values. SNP pairs were considered
to be in strong LD if D' > 0.70. The global haplotype tests
of association were performed under "multiallelic" mode
in haplotype FBAT. Meanwhile, the individual haplotype
tests were conducted under "biallelic" mode in haplotype
FBAT. Family-based association tests were performed
under an additive model in the present study. The signifi-
cance level for all statistical tests was two-tailed P < 0.05.
Results
Seven SNPs in SHANK3 gene were genotyped in 305 Chi-
nese Han autism trios. SNPs rs2106112 and rs13057681
were not polymorphic in our samples. They were not used
as genetic markers for the association analyses. The other
five SNPs (rs9616915, rs6010065, rs2301584,
rs41281537, rs756638) were polymorphic with MAF >
5% and were then used as genetic markers for the associa-
tion study. None of the genotype distributions of these
five SNPs in parents or patients deviated from Hardy-
Weinberg equilibrium (data not shown). Allele frequen-
cies and the results of FBAT for single SNP analyses are
shown in Table 2. None of the five SNPs was significant
evidence (P < 0.05) for preferential transmission of an
allele by FBAT in all samples. To further analyze the pat-
tern of linkage disequilibrium (LD) in our sample, we
computed pairwise LD for all possible combination of the
five SNPs using D'  values (Table 3). Four SNPs
(rs6010065, rs2301584, rs41281537, rs756638) were
found to be in strong LD with each other (D' > 0.7) except
for rs9616915 (Table 3). To determine whether any spe-
cific haplotype would confer a higher risk for autism, we
tested all specific and globe haplotype composed of these
SNPs. Two haplotypes displayed weak association with
autism. These are C-G-G-A (rs6010065- rs2301584-
rs41281537- rs756638, P = 0.040) and G-A (rs41281537-
rs756638, P = 0.047), respectively (Table 3). After 1,000
permutation tests the haplotype C-G-G-A was still associ-
ated with autism (P  = 0.041), but no significance
remained in the haplotype G-A (P = 0.050). No statisti-
cally significant association (P < 0.05) was observed for
any other haplotypes in any set of families in HBAT anal-
Table 1: Information of the primers and PCR-RFLP Analysis
SNP Primer sequence (5'→3') Product (bp) RFLP Allele (bp)
rs9616915 Forward: acctgggggcttcacctgacta
Reverse: cccaacccagcacacagagg
207 Ava II T
(180/27)
C
(121/59/27)
rs13057681 Forward: ccgcaagagccccctggtga
Reverse: caggaggcgctcgtcgatggag
328 Sty IG
(198/130)
C
(328)
rs6010065 Forward: ccttacctgggtgggcatt
Reverse: acggggagggctcttgtg
423 Hinf IG
(166/257)
C
(423)
rs2106112 Forward: ctgagccactcggaggttgct
Reverse: gtccgaccttcaccacgttcac
340
rs2301584, rs41281537, rs756638 Forward: cgccaacagtccaggtcac
Reverse: cagaaggcatgggctgagtt
489
G insertion in exon21 Forward: cgggaggagcggaagtcac
Reverse: ggaccccgttggcaaactct
409
A962G in exon8 Forward: cgcacgccatgtgtgcattcct
Reverse: tctcggggttggggggtcagac
473
splice doner site of intron19 Forward: gcctggggtggggtctgag
Reverse: ttggagcctgggctgtgtg
754
PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; SNP, single nucleotide polymorphism.BMC Medical Genetics 2009, 10:61 http://www.biomedcentral.com/1471-2350/10/61
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yses (data not shown). Moreover, the entire global test for
haplotype transmission revealed a negative result (data
not shown). To detect the de novo mutations reported
before, we sequenced the exon8 (for A962G)[18], part of
exon21 (for G insertion)[17], the donor splice site of
intron19[19] of SHANK3 in 305 probands. However, we
didn't find any genetic variants or the mutations reported
previously.
The SHANK3 gene spans about 60 kb. In Affimatrix SNP
5.0 chip of 240 trios from this sample, it included 16 CNV
probes covering SHANK3 gene and its flanking region.
The smallest distance between two probes was less than
500 bp. In these probes, one CNV probe was located at
intron8 which was reported as a breakpoint of a de novo
deletion[17], and a few CNV probes were quite close to
exon21 which was reported as a breakpoint of a de novo
translocation in 22q13 deletion syndrome[7]. However,
we didn't find any genomic imbalance in all these 240
trios or control (unpublished data).
Discussion
Shank3 is a master synaptic scaffolding protein, acting as
the bridge of some neurotransmitter receptors and the
downstream signal transduction. It has been postulated to
perform important roles in excitatory synapse assembly
[23-26], dendritic formation and maturation[10,27,28].
The de novo alterations of this gene and their roles in the
pathogenesis of autism have been reported by some stud-
ies [17-19]. Based on this evidence, we hypothesized that
the SHANK3 might be a strong candidate gene for autism.
However, there was few evidence of association between
SHANK3  polymorphisms and autism. In the present
study, we investigated the association of SHANK3 poly-
morphisms and autism in 305 Chinese Han trios. We
detected seven dbSNPs of SHANK3, including two non-
polymorphic SNPs rs2106112 (synonymous mutation)
and rs13057681 (H1033D) in our samples. In a family-
based association study for all the other five SNPs we
found no evidence for transmission disequilibrium for
any single marker (P > 0.05), even for the missense SNP
rs9616915C>T which was reported as a non-synonymous
variant identified in ASD[19]. In attempt to identify de
novo genetic variants in SHANK3 that had been reported
previously, we performed mutation screen of exon8, part
of exon21, the donor slpice site of intron19 of SHANK3 in
305 probands with autism, and only identified one novel
synonymous variant (T1231). In addition, the specific
and global-haplotype FBAT tests of association were per-
formed. Four SNPs were located in a block with high LD
including rs6010065, rs2301584, rs41281537, rs756638.
However, only C-G-G-A (rs6010065- rs2301584-
rs41281537- rs756638, P = 0.040) exhibited a weak asso-
ciation with autism in our sample. We didn't detect any
genomic imbalance of SHANK3 and its flanking region in
our sample using Affimetrix 5.0 chip either. Our finding
suggested that SHANK3 doesn't represent a major suscep-
tibility gene for autism in the autism families ascertained
from Chinese Han population.
Several potential reasons might explain the difference
among various reports about SHANK3 gene and autism.
One might be the racial and ethnic differences in genotype
distribution and association with autism risk. For exam-
ple, the allele frequency of the SHANK3 non-synonymous
SNP rs9616915 was obviously different between Chinese
and the other populations in the National Center for Bio-
technology Information (NCBI) gene database. For Euro-
pean (CEU), and Nigeria population, the frequencies of
Table 2: Results of FBAT for the five SNPs
Makers Allele Afreq Families S E (S) Var (S) Z P-values
rs9616915 T 0.911 87 128.000 123.500 24.750 0.905 0.365
C 0.089 87 46.000 50.500 24.750 -0.905 0.365
rs6010065 G 0.500 235 242.000 236.500 79.250 0.618 0.536
C 0.500 235 228.000 233.500 79.250 -0.618 0.536
rs2301584 G 0.811 159 218.000 217.000 46.000 0.147 0.882
A 0.189 159 100.000 101.000 46.000 -0.147 0.882
rs41281537 G 0.858 133 188.000 189.500 37.750 -0.244 0.807
A 0.142 133 78.000 76.500 37.750 0.244 0.807
rs756638 G 0.812 155 218.000 213.000 45.500 0.741 0.458
A 0.188 155 92.000 97.000 45.500 -0.741 0.458
FBAT, family-based association test; Afreq, allelic frequency. Families, number of informative families; S, test statistics for the observed number of 
transmitted alleles; E(S), expected value of S under the null hypothesis (i.e., no linkage or association). Significant P values (< 0.05) are in boldface.
Table 3: Measure of Pairwise Linkage Disequilibrium D (D') 
Between Five SNPs in SHANK3 gene
rs9616915 rs6010065 rs2301584 rs41281537
rs6010065 -0.024(0.58)
rs2301584 -0.003(0.21) 0.082(0.87)
rs41281537 -0.010(0.82) 0.068(0.95) -0.023(0.86)
rs756638 -0.007(0.44) 0.081(0.86) -0.027(0.77) 0.115(1.00)BMC Medical Genetics 2009, 10:61 http://www.biomedcentral.com/1471-2350/10/61
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allele C are 0.533 and 0.383 respectively, but for Chinese
Han population (CHB) it is 0.044. Further, the variety of
the investigated samples should be noticed. The previous
evidence about SHANK3 was always from subjects with
ASD, including autism, Asperger syndrome and PDD-
NOS. Our autism cases only include patients with infan-
tile autism, and not other cases of the etiologically more
heterogeneous ASD. The heterogeneity of the investigated
samples combined with the heterogeneity of neurodevel-
opmental disorders might hamper the understanding of
genetic factors associated with autism. In order to enhance
the possibility of finding relevant genetic cause, the phe-
notype variability in sample should be reduced[29]. In the
present study we examined a relatively homogenous sam-
ple of autism to reduce the heterogeneity. The location of
SHANK3 is at 22q13.3, which is a critical region for 22q13
deletion syndrome that also has autistic behavior. There
are strong evidence that haploinsufficiency of SHANK3
plays a major role in 22q13 deletion syndrome[30].
SHANK3 is very likely to be involved in the pathogenesis
of some mutual phenotypes of ASD and 22q13 deletion
syndrome, such as delay of expressive speech. Further-
more, 22q13 deletion syndrome has a clinical phenotype
overlapping in part the ASD phenotype. So subjects with
22q13 deletion may be included in ASD samples. It is
really critical for the researches on autism to exclude the
22q13 deletion syndrome. We didn't detect any genomic
imbalance of 22q13 in our samples using Affimetrix SNP
5.0 chip. Moreover, although the disruption of SHANK3
seems to be associated with 22q13 deletion syndrome,
there is also contrary evidence that the haploinsufficiency
for 22q13 genes other than SHANK3  have major
effects[31]. The present study indicates that SHANK3 may
not be a critical gene for the etiology of infantile autism in
Chinese Han population. As autism is a heterogeneous
disease, the rare mutations of SHANK3  gene seem to
explain the etiology of only a small proportion of cases
with autism. Sykes et al. reported recently that they didn't
find any CNV or SNP association of SHANK3 within their
ASD sample, although they didn't sequence the gene[32].
Their suggestion that SHANK3 deletions may be limited
to a portion of autism was coincident with ours.
There was few association or linkage study for SHANK3
and autism. Our family-based association study provided
an indication that SHANK3 was not critical for the patho-
genesis of autism in Chinese Han population or only
account for a small proportion of autism individuals. In
addition, our results also reinforce the need for the
detailed LD mapping, mutation screening and CNV anal-
ysis of SHANK3 in different population or other neurode-
velopmental disorders.
Conclusion
The present study did not find strong evidence of
SHANK3  polymorphisms and autism or identify any
described non-synonymous mutations in our cohort.
These might indicate that SHANK3 doesn't represent a
major susceptibility gene for autism in the autism families
ascertained from Chinese Han population.
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